Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

39.12USD
4:00pm EDT
Change (% chg)

$0.68 (+1.77%)
Prev Close
$38.44
Open
$38.10
Day's High
$39.26
Day's Low
$37.63
Volume
249,077
Avg. Vol
355,147
52-wk High
$41.25
52-wk Low
$15.69

Latest Key Developments (Source: Significant Developments)

Portola Pharmaceuticals Q4 loss per share $0.95
Tuesday, 28 Feb 2017 04:05pm EST 

Portola Pharmaceuticals Inc : Portola Pharmaceuticals reports fourth quarter and year-end 2016 financial results and provides corporate update . Q4 loss per share $0.95 . Q4 earnings per share view $-1.12 -- Thomson Reuters I/B/E/S . For fiscal year 2017, portola expects total gaap operating expenses to be between $323 million and $344 million .Portola pharma - for fiscal year 2017, expects total pro-forma operating expenses to be between $290 million & $310 million, excluding stock-based compensation.  Full Article

Portola Pharmaceuticals Inc signed a $150 million royalty agreement with Healthcare Royalty Partners
Friday, 3 Feb 2017 08:00am EST 

Portola Pharmaceuticals Inc : Portola Pharmaceuticals Inc - signed a $150 million royalty agreement with healthcare royalty partners . Portola Pharma - received $50 million at closing and may receive additional $100 million upon FDA approval of andexxa for a tiered, mid-single-digit royalty . Portola Pharmaceuticals Inc - agreement is subject to a maximum total royalty payment of 195 percent of $150 million funded by HCR .Portola - received CRL from FDA regarding biologics license application for andexanet alfa in aug 2016; expects to resubmit application in H1 2017.  Full Article

Portola Pharmaceuticals says FDA accepts NDA for priority review for betrixaban
Friday, 23 Dec 2016 02:12pm EST 

Portola Pharmaceuticals Inc - : Portola Pharmaceuticals announces FDA accepts New Drug Application for priority review and EMA validates marketing authorization application for oral, Factor Xa inhibitor anticoagulant betrixaban . Portola Pharmaceuticals Inc says has been given a Prescription Drug User Fee Act (PDUFA) action date of June 24, 2017 .Portola Pharmaceuticals-EMA validated MAA for betrixaban for extended-duration prophylaxis of VTE in adults with acute medical illness,risk factors.  Full Article

Portola Pharmaceuticals submits NDA to U.S. FDA for betrixaban
Tuesday, 25 Oct 2016 08:00am EDT 

Portola Pharmaceuticals Inc : Submits new drug application to U.S. FDA for betrixaban for extended duration prophylaxis of venous thromboembolism in acute medically ill patients . Sees submission of betrixaban NDA as a first step towards a potential approval in 2017 .Says plans to submit a marketing authorization application for approval of betrixaban in EU by end of this year.  Full Article

BRIEF-Portola Pharmaceuticals receives Complete Response Letter from FDA for biologics license application for AndexXa
Wednesday, 17 Aug 2016 10:57pm EDT 

Corrects headline of brief.Portola Pharmaceuticals Inc : Portola pharmaceuticals receives complete response letter from fda for biologics license application for andexxa(tm) (andexanet alfa) . FDA also asked for additional data to support inclusion of edoxaban and enoxaparin in label .In letter, fda requested that portola provide additional information primarily related to manufacturing.  Full Article

Portola Pharmaceuticals reports Q2 loss per share $1.02
Tuesday, 9 Aug 2016 04:05pm EDT 

Portola Pharmaceuticals Inc : Portola Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-1.20 -- Thomson Reuters I/B/E/S .Q2 loss per share $1.02.  Full Article

Portola Pharmaceuticals, inc announces topline results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Thursday, 24 Mar 2016 07:00am EDT 

Portola Pharmaceuticals, Inc:Says topline data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study.Says there was no statistical difference in major bleeding between the betrixaban and enoxaparin arms in any of these three patient groups.Net clinical benefit with betrixaban was observed.APEX results will be presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress on May 27, 2016.  Full Article

Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Monday, 1 Feb 2016 06:55am EST 

Bristol-Myers Squibb Co:Says the company and Pfizer Inc have entered into a collaboration agreement with Portola Pharmaceuticals Inc to develop and commercialize the investigational agent andexanet alfa in Japan.Under the terms of the agreement, portola will receive an upfront payment of $15 million.Bristol-myers Squibb and Pfizer will co-fund with Portola the development and commercialization of andexanet alfa in japan.Portola will retain rights to andexanet Alfa outside of japan and remain responsible for the manufacturing supply.Under terms, Portola will get potential regulatory milestones of $20 million and sales-based milestones of $70 million.  Full Article

Portola Announces Pricing of Public Offering of Common Stock
Friday, 4 Dec 2015 08:00am EST 

Portola Pharmaceuticals, Inc:Says pricing of its underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $48.00 per share.In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 468,750 shares from Portola at the public offering price.offering is expected to close on December 9, 2015, subject to customary closing conditions.Morgan Stanley, Credit Suisse and Citigroup are acting as joint book-running managers and Cowen and Company is acting as a co-manager for the offering.  Full Article

Portola Pharmaceuticals, Inc announces proposed offering of common stock
Thursday, 3 Dec 2015 04:34pm EST 

Portola Pharmaceuticals, Inc:Announces proposed offering of common stock.Plans to offer 2.6 million shares of its common stock in an underwritten public offering.  Full Article

More From Around the Web

BRIEF-Portola Pharmaceuticals Inc signed a $150 million royalty agreement with Healthcare Royalty Partners

* Portola Pharmaceuticals Inc - signed a $150 million royalty agreement with healthcare royalty partners